Presentation is loading. Please wait.

Presentation is loading. Please wait.

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Published byPhebe Page Modified over 6 years ago

Similar presentations

Presentation on theme: "Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei."— Presentation transcript:

1 Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei Wang, Elizabeth H. Bradley, and Harlan M. Krumholz Circulation Volume 113(9): March 7, 2006 Copyright © American Heart Association, Inc. All rights reserved.

2 US Census tracts located within a 60-minute prehospital time period of a PCI hospital.
Brahmajee K. Nallamothu et al. Circulation. 2006;113: Copyright © American Heart Association, Inc. All rights reserved.

Download ppt "Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei."

Similar presentations

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
Improved Survival After Out-of-Hospital Cardiac Arrest and Use of Automated External DefibrillatorsCLINICAL PERSPECTIVE by Marieke T. Blom, Stefanie G.

Improved Survival After Out-of-Hospital Cardiac Arrest and Use of Automated External DefibrillatorsCLINICAL PERSPECTIVE by Marieke T. Blom, Stefanie G.
From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.
Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2):223-229 July 10, 2012 Copyright.

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.
Early Outcomes of Tricuspid Valve Replacement in Young Children by Heather L. Bartlett, Dianne L. Atkins, Trudy L. Burns, Kelly J. Engelkes, Sarah J. Powell,

Early Outcomes of Tricuspid Valve Replacement in Young Children by Heather L. Bartlett, Dianne L. Atkins, Trudy L. Burns, Kelly J. Engelkes, Sarah J. Powell,
Bariatric Surgery and Cardiovascular Risk Factors by Paul Poirier, Marc-André Cornier, Theodore Mazzone, Sasha Stiles, Susan Cummings, Samuel Klein, Peter.

Bariatric Surgery and Cardiovascular Risk Factors by Paul Poirier, Marc-André Cornier, Theodore Mazzone, Sasha Stiles, Susan Cummings, Samuel Klein, Peter.
Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):2154-2161.

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):
Guide to the Assessment of Physical Activity: Clinical and Research Applications by Scott J. Strath, Leonard A. Kaminsky, Barbara E. Ainsworth, Ulf Ekelund,

Guide to the Assessment of Physical Activity: Clinical and Research Applications by Scott J. Strath, Leonard A. Kaminsky, Barbara E. Ainsworth, Ulf Ekelund,
Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction by Mikhail Kosiborod, Saif S. Rathore, Silvio E. Inzucchi,

Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction by Mikhail Kosiborod, Saif S. Rathore, Silvio E. Inzucchi,
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous.

A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous.
Cost Savings Associated With Implementation of Peer-Reviewed Appropriate Use Criteria for Percutaneous Coronary Interventions  Pranav Puri, Jennifer Carroll,

Cost Savings Associated With Implementation of Peer-Reviewed Appropriate Use Criteria for Percutaneous Coronary Interventions  Pranav Puri, Jennifer Carroll,
Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.
Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes
Circ Cardiovasc Interv

Circ Cardiovasc Interv
by Adolfo Correa, Sophia Greer, and Mario Sims

by Adolfo Correa, Sophia Greer, and Mario Sims
Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,
by Yehuda G. Wolf, Christopher K. Zarins, Geoffrey D

by Yehuda G. Wolf, Christopher K. Zarins, Geoffrey D
Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.

Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.
Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Similar presentations

Ads by Google